Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and moxifloxacin for ethambutol had noninferior efficacy and was safe for the treatment of drug-susceptible pulmonary TB (DS-PTB) compared with the standard 6-month regimen. We explored results among the prespecified subgroup of people with human immunodeficiency virus (HIV) (PWH).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Infect Dis

Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1537-6591

ISSN (Print): 1058-4838

Publication date (Electronic): Feb 08 2023

Volume: 76

Issue: 3

Affiliations

[1 ] Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

[2 ] UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.

[3 ] Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

[4 ] Center for TB Research Innovation, University of Cape Town Lung Institute, Cape Town, South Africa.

[5 ] Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

[6 ] Clinical HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.

[7 ] Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

[8 ] Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.

[9 ] Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.

[10 ] Tuberculosis Research Unit, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

[11 ] Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.

[12 ] Enhancing Care Foundation, Durban University of Technology, Durban, South Africa.

[13 ] Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

[14 ] Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Article

Publisher Item ID: 6679254

DOI: 10.1093/cid/ciac707

PMC ID: 10169427

PubMed ID: 36041016

SO-VID: dcfc0576-aa29-4d04-bd8a-e2975e8f346c

History

Keywords: phase 3 clinical trial,human immunodeficiency virus,moxifloxacin,rifapentine,tuberculosis

Data availability:

Keywords: phase 3 clinical trial, human immunodeficiency virus, moxifloxacin, rifapentine, tuberculosis

Comments

Comment on this article

scite_

Cited by 1

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management
Authors: Peter S. Nyasulu, Cheick Oumar Doumbia, Veranyuy Ngah …

See all cited by